Bajaj Healthcare Limited stock analysis

We expect the revenue mix to gradually normalize towards historical levels as export improves and geopolitical conditions ease over the course of the year. As of 31st March 2026, our net worth stood at INR533 crores, up from INR466 crores last year, and our debt-to-equity ratio improved further to 0.45 as compa red to 0.48 in FY25 and 1.19 in FY24, which is a meaningful deleveraging from over last three years. On cas

Improving asset productivity remained a priority. Higher utilization, better product mix, stronger customer conversion and improved production planning will be central to improving operating leverage and returns. Building an integrated formulations platform The Company’s API expertise provides a foundation for capturing a greater value to supply finished dosaged to the customers.

Strengthening R&D capabilities and building a robust leadership pipeline ensure the organization remains agile, innovative, and future ready. Mitigation BHL mitigates these challenges by diversifying its product portfolio, strengthening backward integration, and focusing on high value and differentiated products. The Company also continues to expand its presence across high growth and regulated markets to enhance lon

Strengthening R&D capabilities and building a robust leadership pipeline ensure the organization remains agile, innovative, and future ready. Mitigation BHL mitigates these challenges by diversifying its product portfolio, strengthening backward integration, and focusing on high value and differentiated products. The Company also continues to expand its presence across high growth and regulated markets to enhance lon

MANAGING DIRECTOR’S BUSINESS REVIEW Bajaj Healthcare Limited Annual Report FY 2025-26 08 Manufacturing with flexibility The Company operates API facilities at T arapur, Savli and Panoli, and a formulations facility at Manjusar. During FY 2025-26, the emphasis was not simply on capacity expansion but on manufacturing flexibility. The ability to switch production between molecules based on customer requirements, market

Sajankumar Rameshwarlal Bajaj Chairman and Managing Director During FY 2025-26, we strengthened our research platform, progressed product development programmes, expanded regulatory preparation, enhanced manufacturing capabilities and deepened scientific resources. Several initiatives moved through regulatory approvals, customer qualification, validation, scale- up and market introduction. Their contribution will the

The Company is also a prominent player in India’s nutraceutical market, manufacturing high-quality products such as Ascorbic Acid IP , Chlorhexidine base, Magnesium-L- Threonate, Sodium Ascorbate, and Ferrous Ascorbate. Backed by a strong global presence, BHL exports APIs to more than 60 countries, supported by an experienced in-house product registration team that facilitates seamless access to regulated and emergin

The facility enhance our capabilities across solid dosage form and provides a strategic platform for expanding our formulation and oncology businesses. Following the receipt of the request approval and licensing, commercial production is expected to commence by second half of 2027. With that, now let me hand over a call to Mr.

Anil Jain: Anything between, 8% to 9%. And sir, the other 8 to 10 products where we are implementing backward integration measures, what percentage of our revenue would come from that and what is the margin improvement can we expect? Anil Jain: You can put together around 20% to 25% will come from that 8 to 10 products and there will be a marginal increase from 1% to 2%.